EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Efficacy of pembrolizumab in urothelial cancer: A systematic review and meta-analysis

Vinay Eruvuri, Nitish Nichenametla, Monish Konda, Bala Sathvika Duggimpudi, Yethindra Vityala

Bladder · 2025

DOI: 10.14440/bladder.0249 ↗
AbstractBibliografische Angaben

Abstract

Background: Urothelial bladder cancer is a major health challenge owing to its high incidence, elevated mortality rates, and clinical diversity. Objective: This systematic review and meta-analysis assesses the efficacy of pembrolizumab in the treatment of non-muscle-invasive bladder cancer (NMIBC), muscle-invasive bladder cancer (MIBC), and metastatic urothelial carcinoma (mUC). After applying the inclusion and exclusion criteria, a literature search of PubMed, Scopus, and Web of Science (January 2020–June 2025) identified eight studies on NMIBC, MIBC, and mUC for the final analysis. Analysis revealed an advantage of pembrolizumab-based treatment (odds ratio [OR]: 1.86; 95% confidence interval [CI]: 1.70–2.03). Subgroup analyses showed the effectiveness in MIBC (OR: 1.88; 95% CI: 1.65–2.12) and mUC (OR: 1.94; 95% CI: 1.82–2.11). In contrast, the NMIBC subgroup lacked significance (OR: 1.28; 95% CI: 0.86–1.91), reflecting the evidence from small, early-phase studies. Pembrolizumab showed improved pathological complete response, progression-free survival, and disease-free survival in groups with elevated programmed death-ligand 1 expression and a high tumor mutational burden. Conclusion: Pembrolizumab is highly effective in treating MIBC and mUC; however, its impact on NMIBC remains uncertain. The limited number of studies and brief follow-up periods highlight the need for larger trials with long-term survival data.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →